Genkyotex S.A.
GKTX.PA
Euronext Paris3.21
EUR
- -
- -
Genkyotex S.A.
GKTX.PA
(Euronext Paris)
Recent
price
3.21
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Genkyotex S.A. (GKTX.PA) develops small-molecule inhibitors targeting NADPH oxidase (NOX) enzymes for treating diseases involving fibrosis, inflammation, neurodegeneration, and related conditions; its lead product candidate, setanaxib (formerly GKT831), is a dual NOX1/NOX4 inhibitor in Phase II clinical trials for primary biliary cholangitis and diabetic kidney disease, while preclinical candidate GKT771 targets NOX1 for inflammation and pain. Founded in 2006 and headquartered in Saint-Julien-en-Genevois, France, the company operates primarily in Europe through facilities in France and Switzerland, focusing on biopharmaceutical research and development in the biotechnology sector. Genkyotex S.A. and its Swiss affiliate are wholly owned subsidiaries of Calliditas Therapeutics AB following the Swedish firm's 2020 acquisition of a controlling interest for approximately EUR 32 million in cash plus milestones, marking a major strategic integration that supports ongoing clinical advancement of its NOX inhibitor platform.